Latest Articles

Publication Date
Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative - Nature

Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative Nature

Published: Nov. 11, 2025, 8:42 p.m.
"Black box" warning from menopause hormone therapy scrapped by FDA - Axios

"Black box" warning from menopause hormone therapy scrapped by FDA Axios

Published: Nov. 11, 2025, 4:54 p.m.
Case Report: Diagnostic challenges in cervical small cell neuroendocrine carcinoma of a reproductive-age woman.

Small cell neuroendocrine carcinoma of the cervix (SCNEC) is a rare and highly aggressive malignancy with a poor prognosis. We report the case of a 36-year-old nulliparous woman with a …

Published: Nov. 10, 2025, midnight
Analysis of Risk Factors Associated With Persistent Noncyclic Pelvic Pain Despite Hormonal Treatment in Patients With Endometriosis.

To identify risk factors that predict the persistence of noncyclical pelvic pain in patients with endometriosis despite receiving hormone therapy.

Published: Nov. 9, 2025, midnight
Evaluation of microecological therapy in endometriosis through modulation of the gut microbiota.

Endometriosis is a chronic inflammatory disease significantly affecting women's health and quality of life. The recent evidence highlights the role of gut microbiota dysbiosis in endometriosis pathogenesis, suggesting that gut …

Published: Nov. 7, 2025, midnight
Presacral Clear Cell Carcinoma of Müllerian Origin 20 Years After Hysterectomy and Bilateral Salpingo-Oophorectomy: A Case Report and Literature Review.

Primary presacral clear cell carcinoma (CCC) of Müllerian origin is extremely rare. Malignant transformation of endometriosis is a known phenomenon, though typically involving the ovaries or pelvic peritoneum. Retroperitoneal presentation, …

Published: Nov. 7, 2025, midnight
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Channel Medsystems Surpasses 5,000 Cerene® Cryotherapy - GlobeNewswire

Channel Medsystems Surpasses 5,000 Cerene® Cryotherapy GlobeNewswire

Published: Nov. 6, 2025, 4 p.m.
Pelvic Floor Therapy for Endometriosis - HealthCentral

Pelvic Floor Therapy for Endometriosis HealthCentral

Published: Nov. 6, 2025, 12:44 p.m.
Sonographic and Clinical Progression of Adenomyosis and Coexisting Endometriosis: Long-Term Insights and Management Perspectives.

Objectives: To evaluate the impact of hormonal therapy on the evolution of painful symptoms in premenopausal women with adenomyosis, with or without concomitant endometriosis, over an 18-month follow-up period. This …

Published: Nov. 6, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!